EloraTZP Phase 2b: eloralintide plus tirzepatide beats tirzepatide 15 mg

Lilly reported Phase 2b results for EloraTZP, a combination of its amylin agonist eloralintide and tirzepatide, on September 30, 2026. At 48 weeks in adults with obesity and type 2 diabetes, the top combination dose produced up to 23.3% weight loss versus 14.8% with tirzepatide 15 mg alone. Discontinuations for adverse events were higher than with tirzepatide, and Lilly plans to start Phase 3 trials of a co-formulated product in the fourth quarter of 2026.

• 48-week weight loss up to 23.3% vs 14.8% with tirzepatide 15 mg
• A1C reduction up to 2.9% vs 2.4% with tirzepatide 15 mg
• Trial of 367 adults with obesity or overweight and type 2 diabetes
• Adverse-event discontinuation 10.8-27.0% in EloraTZP arms vs 2.9% for tirzepatide
• Phase 3 of co-formulated EloraTZP planned to start in Q4 2026